Free Trial

Imunon (IMNN) Competitors

Imunon logo
$7.00 -0.55 (-7.24%)
Closing price 04:00 PM Eastern
Extended Trading
$6.98 -0.02 (-0.29%)
As of 05:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IMNN vs. COEP, XLO, LVTX, HYPD, KALA, ITRM, AKTX, MAAQ, KPTI, and SNYR

Should you be buying Imunon stock or one of its competitors? The main competitors of Imunon include Coeptis Therapeutics (COEP), Xilio Therapeutics (XLO), LAVA Therapeutics (LVTX), Hyperion DeFi (HYPD), KALA BIO (KALA), Iterum Therapeutics (ITRM), Akari Therapeutics (AKTX), Mana Capital Acquisition (MAAQ), Karyopharm Therapeutics (KPTI), and Synergy CHC (SNYR). These companies are all part of the "pharmaceutical products" industry.

Imunon vs. Its Competitors

Imunon (NASDAQ:IMNN) and Coeptis Therapeutics (NASDAQ:COEP) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, media sentiment, analyst recommendations and institutional ownership.

Imunon presently has a consensus target price of $232.50, suggesting a potential upside of 3,221.43%. Given Imunon's stronger consensus rating and higher possible upside, research analysts clearly believe Imunon is more favorable than Coeptis Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Imunon
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.75
Coeptis Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Coeptis Therapeutics' return on equity of -282.39% beat Imunon's return on equity.

Company Net Margins Return on Equity Return on Assets
ImunonN/A -427.98% -175.03%
Coeptis Therapeutics N/A -282.39%-127.23%

Coeptis Therapeutics has lower revenue, but higher earnings than Imunon. Imunon is trading at a lower price-to-earnings ratio than Coeptis Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Imunon$500K245.56-$18.62M-$1.36-5.15
Coeptis TherapeuticsN/AN/A-$10.88M-$5.80-2.01

In the previous week, Imunon had 3 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 6 mentions for Imunon and 3 mentions for Coeptis Therapeutics. Coeptis Therapeutics' average media sentiment score of 1.28 beat Imunon's score of -0.19 indicating that Coeptis Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Imunon
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Coeptis Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Imunon has a beta of 1.93, suggesting that its stock price is 93% more volatile than the S&P 500. Comparatively, Coeptis Therapeutics has a beta of -0.63, suggesting that its stock price is 163% less volatile than the S&P 500.

4.5% of Imunon shares are held by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are held by institutional investors. 6.0% of Imunon shares are held by company insiders. Comparatively, 24.3% of Coeptis Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Imunon beats Coeptis Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Imunon News Delivered to You Automatically

Sign up to receive the latest news and ratings for IMNN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IMNN vs. The Competition

MetricImunonMED IndustryMedical SectorNASDAQ Exchange
Market Cap$122.78M$3.04B$5.74B$9.51B
Dividend YieldN/A2.40%4.60%3.99%
P/E Ratio-5.1521.1828.1120.03
Price / Sales245.56337.65460.63103.88
Price / CashN/A43.2336.5559.01
Price / Book24.148.368.655.90
Net Income-$18.62M-$55.19M$3.25B$258.66M
7 Day Performance-15.46%5.89%4.20%2.23%
1 Month Performance-44.16%17.63%10.83%12.77%
1 Year Performance-59.42%5.10%34.67%19.36%

Imunon Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IMNN
Imunon
1.9479 of 5 stars
$7.00
-7.2%
$232.50
+3,221.4%
-58.4%$122.78M$500K-5.1530Stock Split
COEP
Coeptis Therapeutics
0.6865 of 5 stars
$10.70
+0.2%
N/A+117.3%$37.53MN/A-1.842Positive News
Gap Up
XLO
Xilio Therapeutics
2.721 of 5 stars
$0.70
-3.4%
$4.00
+473.5%
-26.2%$37.39M$6.34M-0.8370Positive News
LVTX
LAVA Therapeutics
2.3671 of 5 stars
$1.44
+1.4%
$3.17
+119.9%
-27.7%$37.35M$11.98M-1.3860Positive News
HYPD
Hyperion DeFi
1.1268 of 5 stars
$11.64
-9.6%
$2.00
-82.8%
-92.8%$37.13M$60K-0.2040Positive News
Gap Up
KALA
KALA BIO
3.9657 of 5 stars
$5.70
-0.7%
$13.00
+128.1%
-0.3%$37.04MN/A-0.6930
ITRM
Iterum Therapeutics
2.05 of 5 stars
$0.87
-5.0%
$9.00
+933.3%
-34.3%$36.66MN/A-0.8810Positive News
AKTX
Akari Therapeutics
2.6506 of 5 stars
$1.14
+0.4%
$5.00
+340.5%
-71.9%$36.36MN/A0.009High Trading Volume
MAAQ
Mana Capital Acquisition
N/A$4.30
-6.9%
N/A+812.7%$34.94MN/A0.001Gap Up
KPTI
Karyopharm Therapeutics
3.8298 of 5 stars
$4.02
+4.4%
$37.40
+830.3%
-68.8%$33.26M$145.24M-0.30380
SNYR
Synergy CHC
4.0617 of 5 stars
$3.50
-3.0%
$10.00
+185.7%
N/A$33.19M$33.59M0.0040

Related Companies and Tools


This page (NASDAQ:IMNN) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners